Role of enhancement modifications in evaluating tumor response to immunotherapy in metastatic renal cell carcinoma.

Michele Dionese,Francesco Pierantoni,Elisabetta Bezzon, Enrico Cumerlato,Davide Bimbatti,Umberto Basso,Marco Maruzzo,Vittorina Zagonel

Tumori（2023）

引用 0|浏览1

暂无评分

摘要

Choi criteria seemed to be able to predict clinical benefit in a higher proportion of patients with renal cell carcinoma treated with immunotherapy than RECIST criteria. Partial response according to RECIST was confirmed as a predictor of longer progression-free survival and overall survival.

查看译文

关键词

Choi,Metastatic renal cell carcinoma,RECIST,immunotherapy,response evaluation,tumor attenuation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要